3-(4,4-dimethoxyphenyl)-1-phenylpyrazole-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(4,4-dimethoxyphenyl)-1-phenylpyrazole-4-carboxylic acid
• 英文别名: 3-(3,4-dimethoxyphenyl)-1-phenyl-1H-pyrazole-4-carboxylic acid；3-(3,4-dimethoxyphenyl)-1-phenylpyrazole-4-carboxylic acid
• 化学式: C₁₈H₁₆N₂O₄
• mdl: MFCD02714738
• 分子量: 324.336
• InChiKey: TZYXKOWJIFWEAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  73.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(4,4-dimethoxyphenyl)-1-phenylpyrazole-4-carboxylic acid 以88%的产率得到3-(4,4-dimethoxyphenyl)-1-phenyl-4-pyrazolecarbonyl chloride
  参考文献：
  名称：

  摘要：

  3-Aryl(heteryl)-1-phenyl-4-pyrazolecarbonyl isothiocyanates were synthesized by treatment of 3-aryl(heteryl)-1-phenyl-4-pyrazolecarbonyl chlorides with lead, sodium, or ammonium thiocyanate. Their reactions with amines, hydrazines, and acylhydrazines gave the corresponding thioureas and thiosemicarbazides.

  DOI：

  10.1023/a:1016394311649
• 作为产物：
  描述：

  1-(1-(3,4-dimethoxyphenyl)ethylidene)-2-phenylhydrazine 在 potassium permanganate 、 potassium hydroxide 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.33h， 生成 3-(4,4-dimethoxyphenyl)-1-phenylpyrazole-4-carboxylic acid
  参考文献：
  名称：

  基于结构的吡唑酰胺作为新型 ERRγ 反向激动剂的发现

  摘要：

  雌激素相关受体-γ (ERRγ) 是一种孤儿核受体，与雌激素受体（ERα 和 β）具有高度结构相似性。该受体的内源性配体尚未确定。迄今为止，已知只有两类分子——芪（己烯雌酚、4-羟基三苯氧胺和 GSK5182）和黄酮醇（山奈酚）可调节受体的转录活性。此外，这些药物对 ERRγ 缺乏选择性，这表明需要一种新的反向激动剂。因此，使用虚拟筛选将吡唑酰胺 7 鉴定为新型 ERRγ 反向激动剂。基于结构的化合物多样化和优化进一步导致衍生物19的鉴定作为 ERRγ 的有效反向激动剂，对包括 ERR 家族在内的其他核受体具有选择性。Pyrazolamide 19对 ERRγ 表现出很强的亲和力，并抑制铁调素、纤维蛋白原和糖异生基因的表达，这表明这些化合物可能具有抗菌、抗凝血和抗糖尿病活性。

  DOI：

  10.1016/j.ejmech.2023.115174

文献信息

• [EN] PYRAZOLE DERIVATIVES AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS<br/>[FR] COMPOSES ET COMPOSITIONS DE MODULATION
  申请人：CAREX SA

  公开号：WO2004043951A1

  公开（公告）日：2004-05-27

  The present invention relates to compounds, compositions and methods useful for modulating nuclear receptors activity in cells, and for treating and/or preventing various diseases and conditions mediated by said nuclear receptors, including metabolic or cell proliferative disorders. According to particular aspects, the present invention relates to compounds, compositions and methods useful for modulating activities of the Peroxisome Proliferator Activated Receptors (PPARs) and for treating and/or preventing various disease and conditions mediated by said nuclear receptors. More specifically, it relates to Peroxigome Proliferator Activated Receptor-gamma (PPAR-gamma) ligands, which are useful in the modulation of blood glucose levels and in the increase of insulin sensitivity in patients in need thereof. The properties of the compounds and compositions of the invention make these PPAR ligands particularly useful in the treatment of those diseases and conditions including diabetes, atherosclerosis, hyperglycemia, dyslipidemia, obesity, syndrome X, insulin resistance, hypertension, neuropathy, microvascular diseases (e.g. retinopathy, nephropathy), macrovascular diseases (e.g. myocardial infarction, stroke, heart failure) in mammals.